Vivimed Labs Ltd

₹ 5.79 4.70%

02 Apr - close price

vivimedlabs.com BSE: 532660 NSE: VIVIMEDLAB

About

Vivimed Labs Ltd, established in 1988, is primarily engaged in the Business of Active Pharmaceuticals Ingredients, CDMO Finished Dosage Formulation, Specialty Chemicals and Retail Branded Formulation manufacturing.^[1]^[2]

Key Points

Special Resolution^[1]
In Dec'25, Under Special Resolution Company asked for approval for making an application to initiate a pre-packaged insolvency resolution process under the Insolvency and Bankruptcy Code, 2016, which was approved by shareholders.

Website BSE NSE

Market Cap ₹ 48.0 Cr.
Current Price ₹ 5.79
High / Low ₹ 29.4 / 5.15
Stock P/E
Book Value ₹ 5.50
Dividend Yield 0.00 %
ROCE -6.45 %
ROE -42.6 %
Face Value ₹ 2.00

Add ratio to table

Edit ratios

Pros

Stock is trading at 1.05 times its book value

Cons

Company has low interest coverage ratio.
The company has delivered a poor sales growth of -17.8% over past five years.
Promoter holding is low: 7.77%
Company has a low return on equity of -84.0% over last 3 years.
Contingent liabilities of Rs.183 Cr.
Company might be capitalizing the interest cost
Company has high debtors of 161 days.
Promoter holding has decreased over last 3 years: -13.2%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
	51	40	33	30	37	36	25	22	34	23	18	19	12
	57	203	33	36	36	65	36	23	34	25	18	20	23
Operating Profit	-6	-164	-0	-5	1	-29	-11	-1	-0	-2	-1	-1	-11
OPM %	-12%	-412%	-1%	-18%	2%	-79%	-45%	-4%	-1%	-11%	-3%	-7%	-96%
	0	0	0	2	0	7	0	0	0	4	0	0	0
Interest	9	8	11	12	13	-34	0	0	0	1	1	2	1
Depreciation	4	95	4	4	4	5	4	4	6	5	5	5	4
Profit before tax	-19	-267	-15	-20	-17	7	-15	-5	-7	-4	-6	-7	-17
Tax %	0%	-1%	0%	0%	-3%	24%	0%	0%	0%	0%	0%	0%	0%
	-19	-265	-15	-20	-16	6	-15	-5	-7	-4	-6	-7	-17
EPS in Rs	-2.31	-31.94	-1.85	-2.36	-1.95	0.66	-1.82	-0.60	-0.84	-0.53	-0.66	-0.90	-2.00
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
	432	430	319	570	261	252	277	210	218	177	137	104	71
	328	323	233	319	183	184	237	182	227	365	170	118	86
Operating Profit	104	107	86	250	78	67	40	28	-9	-188	-33	-15	-16
OPM %	24%	25%	27%	44%	30%	27%	14%	13%	-4%	-106%	-24%	-14%	-22%
	2	1	1	9	2	9	-0	6	1	0	10	4	5
Interest	49	64	57	59	53	53	43	42	40	36	2	3	5
Depreciation	18	21	19	27	18	18	17	16	17	107	18	19	18
Profit before tax	39	24	11	173	9	5	-21	-24	-65	-330	-44	-32	-34
Tax %	31%	22%	28%	27%	-12%	-20%	-8%	-1%	4%	-1%	0%	0%
	27	19	8	126	10	6	-19	-23	-68	-328	-44	-32	-34
EPS in Rs	3.29	2.34	1.00	15.59	1.20	0.75	-2.31	-2.81	-8.17	-39.56	-5.35	-3.80	-4.09
Dividend Payout %	2%	0%	0%	3%	33%	0%	0%	0%	0%	0%	0%	0%

Compounded Sales Growth
10 Years:	-13%
5 Years:	-18%
3 Years:	-22%
TTM:	-40%

Compounded Profit Growth
10 Years:	%
5 Years:	%
3 Years:	15%
TTM:	-57%

Stock Price CAGR
10 Years:	-23%
5 Years:	-20%
3 Years:	-6%
1 Year:	%

Return on Equity
10 Years:	-9%
5 Years:	-33%
3 Years:	-84%
Last Year:	-43%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Sep 2025
Equity Capital	16	16	16	16	17	17	17	17	17	17	17	17	17
Reserves	359	358	353	545	551	556	537	508	441	117	73	42	29
	636	698	599	571	446	348	304	323	357	377	375	375	375
	193	231	397	229	243	234	210	247	258	286	217	206	219
Total Liabilities	1,203	1,303	1,365	1,361	1,255	1,155	1,067	1,095	1,072	796	681	639	640
	397	377	387	433	405	381	356	416	429	343	326	315	305
CWIP	16	63	41	59	43	64	70	58	40	21	21	17	17
Investments	228	230	230	88	152	88	88	161	161	161	59	59	59
	563	633	708	781	656	622	554	459	442	271	276	248	259
Total Assets	1,203	1,303	1,365	1,361	1,255	1,155	1,067	1,095	1,072	796	681	639	640

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
	-45	41	-54	28	207	82	75	180	25	33	-97	6
	-149	-50	-11	30	-38	56	3	-138	-11	-2	100	-4
	193	9	59	-50	-175	-123	-91	-46	-13	-35	-6	-3
Net Cash Flow	-0	1	-7	8	-6	15	-13	-5	1	-3	-2	-1
Free Cash Flow	-61	-6	-65	53	232	66	78	115	14	31	-99	2
CFO/OP	-47%	39%	-63%	16%	285%	160%	205%	654%	-280%	-17%	291%	-39%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days	155	194	264	144	234	148	118	133	106	104	159	161
Inventory Days	265	410	744	579	1,236	1,284	640	954	608	106	340	354
Days Payable	61	84	68	92	99	160	75	124	95	77	211	211
Cash Conversion Cycle	359	520	940	632	1,371	1,271	683	963	619	134	289	304
Working Capital Days	121	132	291	168	345	375	319	213	116	-299	-311	-513
ROCE %	10%	8%	7%	22%	6%	6%	3%	2%	-3%	-44%	-9%	-6%

Insights

In beta

Mar 2015

Mar 2016

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Manufacturing Facilities
Number

xx	xx	xx	xx	xx	xx	x	x	x	x	x
x	x	x	x	x	x	x	x	x		x
x,xxx	x,xxx	xxx	x,xxx	xxx	x,xxx	xxx	xxx	xxx		xxx
xxx	xxx	xxx	xxx	xxx	xxx
xx	xx	xx	xx		xx
x			x	x
x			x		x

Please log in to see hidden values.

R&D Centers
Number

Total Employee Strength
Number

Drug Master Files (DMF) - Worldwide
Number

Type II DMFs filed with USFDA
Number

Commercialized ANDAs
Number

Finished Dosage Formulation Capacity
Billion Units (SOD)

Shareholding Pattern

Numbers in percentages

7 Recently

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
	20.94%	20.94%	20.94%	20.94%	20.94%	20.94%	20.94%	20.94%	20.94%	7.76%	7.76%	7.76%
	1.64%	1.64%	1.64%	1.64%	1.64%	1.64%	1.64%	1.64%	1.64%	1.64%	1.64%	1.64%
	0.12%	0.12%	0.12%	0.12%	0.12%	0.12%	0.12%	0.12%	0.12%	0.12%	0.12%	0.12%
	77.30%	77.30%	77.29%	77.30%	77.29%	77.30%	77.30%	77.30%	77.30%	90.47%	90.47%	90.47%
No. of Shareholders	50,683	49,503	49,038	49,027	49,016	49,012	49,003	49,005	48,957	48,928	48,925	49,221

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Dec 2025
	36.48%	36.64%	34.39%	32.79%	28.57%	21.98%	20.94%	20.94%	20.94%	7.76%
	4.23%	5.24%	4.07%	3.56%	3.10%	1.64%	1.64%	1.64%	1.64%	1.64%
	0.33%	0.30%	0.48%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	0.12%	0.12%	0.12%	0.12%	0.12%	0.12%	0.12%	0.12%	0.12%	0.12%
	58.85%	57.71%	60.94%	63.53%	68.21%	76.27%	77.30%	77.29%	77.30%	90.47%
No. of Shareholders	19,274	30,575	33,380	30,638	37,989	53,110	50,683	49,016	48,957	49,221

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

All

Annual reports

Credit ratings

Concalls

Aug 2019

Transcript

AI Summary
PPT
Mar 2019

Transcript

AI Summary
PPT
Nov 2018

Transcript

AI Summary
PPT
Aug 2018

Transcript

AI Summary
PPT
Jun 2018

Transcript

AI Summary
PPT
Feb 2018

Transcript

AI Summary
PPT
Nov 2017

Transcript

AI Summary
PPT
Aug 2017
Transcript PPT
Nov 2016
Transcript PPT
Aug 2016
Transcript PPT
May 2016
Transcript PPT
Aug 2015

Transcript

AI Summary
PPT